Novo Nordisk CEO Signals Interest in M&A to Bolster Drug Pipeline
Mike Doustdar, CEO of Novo Nordisk A/S (NVO), stated during an interview with CNBC that the company is considering mergers and acquisitions as a strategy amid increasing competition. The pharmaceutical giant aims to identify gaps in its drug pipeline and explore opportunities where external innovation could enhance its offerings. Doustdar emphasized that if there are areas where other companies have developed or are about to introduce superior drugs, Novo Nordisk would be open to acquiring those capabilities through M&A. This comes as the weight-loss market becomes increasingly crowded with new entrants and therapies.
Tickers: $NVO
Topics: Mergers and acquisitions Pharmaceuticals Weight-loss drugs